Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug 26;20(1):226.
doi: 10.1186/s12890-020-01247-y.

Author response to "lack of benefit from low dose computed tomography in screening for lung cancer"

Kai-Lin Huang  1   2 , Shih-Yuan Wang  1 , Wan-Chen Lu  1 , Ya-Hui Chang  1 , Jian Su  3   4 , Yen-Ta Lu  5   6
Affiliations
Comment

Author response to "lack of benefit from low dose computed tomography in screening for lung cancer"

Kai-Lin Huang et al. BMC Pulm Med. .

Abstract

We explain to Dr. Benjamin (corresponding author) about why low-dose computed tomography reduce lung cancer mortality without significantly reducing all-cause mortality. We also conduct an up-to-date meta-analysis to evaluate low-dose computed tomography clinical effectiveness compared with usual care of lung cancer screening.

Keywords: LDCT; Low-dose computed tomography; Lung cancer screening; Meta-analysis; Mortality.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Forest plots of comparisons between low-dose computed tomography (LDCT) versus no screening or chest radiology (CXR) for (a) lung cancer mortality (b) all-cause mortality using update data
See this image and copyright information in PMC

Comment on

References

    1. Huang K-L, Wang S-Y, Lu W-C, Chang Y-H, Su J, Lu Y-T. Effects of low-dose computed tomography on lung cancer screening: a systematic review, meta-analysis, and trial sequential analysis. BMC Pulm Med. 2019;19(1):126. doi: 10.1186/s12890-019-0883-x. - DOI - PMC - PubMed
    1. Black WC, Haggstrom DA, Gilbert Welch H. All-cause mortality in randomized trials of Cancer screening. J Natl Cancer Inst. 2002;94(3):167–173. doi: 10.1093/jnci/94.3.167. - DOI - PubMed
    1. Aberle DR, Black WC, Chiles C, Church TR, Gareen IF, Gierada DS, Mahon I, Miller EA, Pinsky PF, Sicks JD. Lung cancer incidence and mortality with extended follow-up in the national lung screening trial. J Thorac Oncol. 2019;14(10):1732–42. - PMC - PubMed
    1. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–513. doi: 10.1056/NEJMoa1911793. - DOI - PubMed
    1. Becker N, Motsch E, Trotter A, Heussel CP, Dienemann H, Schnabel PA, Kauczor HU, Maldonado SG, Miller AB, Kaaks R, et al. Lung cancer mortality reduction by LDCT screening-results from the randomized German LUSI trial. Int J Cancer. 2020;146(6):1503–1513. doi: 10.1002/ijc.32486. - DOI - PubMed